Novocure Limited · NASDAQ:NVCR
Novocure — Investor Day (June 2025)
43 slides from Novocure's investor day presentation, Jun 2, 2025
Slide 1: PANOVA-3 Investor Event
[Confidential] © 2025 Novocure GmbH© 2025 Novocure GmbH 1 PANOVA-3 Investor Event May 31, 2025 – Chicago Exhibit 99.3
Slide 2: Entering a new era with expanding oncology platform
© 2025 Novocure GmbH 2 ` entering a new era with expanding oncology platform POSITIVE PHASE 3 DATA IN LOCALLY ADV. PANCREATIC CANCER POSITIVE PHASE 3 DATA IN BRAIN METS FROM NSCLC COMMERCIALLY LAUNCHED IN NSCLC ESTABLISHED FOOTPRINT IN GLIOBLASTOMA NSCLC, non-small cell lung cancer; mets, metastases
Slide 3: Agenda
© 2025 Novocure GmbH 3 agenda TTFields: A Multi-Indication Platform | Ashley Cordova Pancreatic Cancer Overview | Nicolas Leupin, M.D., Ph.D. PANOVA-3 Clinical Trial Results | Vincent Picozzi, M.D. Novocure Corporate Update | Ashley Cordova Q&A | Vincent Picozzi, M.D., Novocure Executive Team
Slide 4: Together with our patients, we strive to extend survival
© 2025 Novocure GmbH 4 together with our patients, we strive to extend survival in some of the most aggressive forms of cancer
Slide 5: TTFields delivered through a portable, wearable medical device
© 2025 Novocure GmbH 5 TTFields are delivered through a portable, wearable medical device disposable transducer arrays field generator
Slide 6: TTFields: platform therapy with positive phase trials
© 2025 Novocure GmbH 6 TTFields: platform therapy with 4 positive phase 3 trials in cancers with significant unmet needs glioblastoma non-small cell lung cancer brain mets from NSCLC locally advanced pancreatic cancer >$600m Annual revenue1 >4,000 Patients on therapy2 H2 2025 Planned regulatory subm
Slide 7: [ ]
[Confidential] © 2025 Novocure GmbH © 2025 Novocure GmbH 7
Slide 8: Pancreatic cancer cases are on the rise globally
© 2025 Novocure GmbH 8 pancreatic cancer cases are on the rise globally Global ASR Incidence and Predicted Rates and Case Numbers From 1990-20301 UNITED STATES • Annual pancreatic cancer incidence: 67,000 • Annual PANOVA-3 eligible patients: 16,000 Between 1990 and 2019, global trends in pancreatic
Slide 9: Challenges of treating pancreatic cancer
© 2025 Novocure GmbH 9 PROGNOSIS1 • 67,000+ new cases diagnosed annually in the U.S. • 3rd leading cause of cancer-related death • 5-year survival rate of only 13% DIAGNOSIS • Limited nonspecific symptoms of early-stage disease • Most patients diagnosed at advanced stage • Systemic treatment options
Slide 10: Evaluating the standard of care
© 2025 Novocure GmbH 10 evaluating the standard of care: comparable efficacy profiles with differing toxicity and dosing burden GEMCITABINE + NAB-PACLITAXEL FOLFIRINOX GUIDELINES1 TOXICITY TREATMENT REGIMEN NCCN Category 2A recommendation; ~50% utilization NCCN Category 2A recommendation; ~50% utili
Slide 11: PANOVA-3 recognized at ASCO
© 2025 Novocure GmbH 11 late breaking oral abstract published in journal of clinical oncology featured in ‘best of ASCO’ positive phase 3 PANOVA-3 trial recognized at ASCO `
Slide 12: ASCO PANOVA-3 trial results
© 2025 Novocure GmbH 12 ASCO phase 3 PANOVA-3 trial results VINCENT PICOZZI, M.D. Director of Pancreatic & Biliary Duct Cancer Virginia Mason Franciscan Health Leads the largest single practice in pancreatic cancer in the nation and has an active clinical research program, both at Virginia Mason and
Slide 13: PANOVA-3: Phase 3 study of TTFields with GnP in LA-PAC
PRESENTED BY: PANOVA-3: Phase 3 study of Tumor Treating Fields (TTFields) with gemcitabine and nab-paclitaxel (GnP) for locally advanced pancreatic adenocarcinoma (LA-PAC) Vincent Picozzi, Hani Babiker, Sreenivasa Chandana, Bohuslav Melichar, Anup Kasi, Jin Gang, Javier Gallego, Andrea Bullock, Hao
Slide 14: Key Takeaway Points/Conclusions
PRESENTED BY: Key Takeaway Points/Conclusions 14 Survival benefit for patients is supported by significantly improved QoL and pain-free survival* compared with GnP alone Dr Vincent Picozzi The only frequently reported TTFields toxicity was localized skin reactions *as the time to a ≥ 20-point increa
Slide 15: LA-PAC, a high unmet need
PRESENTED BY: LA- PAC, a high unmet need 15 • Pancreatic adenocarcinoma remains a high unmet need with a modest 5-year survival rate of 8%1,2 About 30–35% of patients present with LA-PAC* and only 10–15% of them will be eligible for potentially curative surgery3 The remaining patients are incurabl
Slide 16: TTFields therapy
PRESENTED BY: TTFields therapy 16 • TTFields are electric fields that disrupt processes critical for cancer cell division1-3 and may trigger an enhanced antitumor immune response • TTFields therapy is delivered noninvasively to the tumor site via a portable device that consists of a field generator
Slide 17: PANOVA-3 study design
PRESENTED BY: PANOVA-3 study design 17 Dr Vincent Picozzi R 1:1 Gemcitabine 1000 mg/m2† Nab-paclitaxel 125 mg/m2† TTFields therapy* Gemcitabine 1000 mg/m2† Nab-paclitaxel 125 mg/m2† Follow-up Q4W (CT scan Q8W) Follow-up Q4W (CT scan Q8W) Monthly survival follow-up after local progression N = 571 Pat
Slide 18: PANOVA-3: Endpoints and statistical analyses
PRESENTED BY: PANOVA-3: Endpoints and statistical analyses 18 Dr Vincent Picozzi *Compared using one-sided t-test after the directionality of the effect was established; †Compared using one-sided Fisher’s exact test with α=0.05. GnP, gemcitabine/nab-paclitaxel; ITT, intent-to-treat population; KM, K
Slide 19: Patient disposition
PRESENTED BY: Patient disposition 19 Dr Vincent Picozzi † One full GnP cycle is defined as 3 complete administrations per cycle. GnP, gemcitabine/nab-paclitaxel; ITT, intent-to-treat population; mITT, modified intent-to-treat population; TTFields, Tumor Treating Fields.. Screened N=753 Randomized N=
Slide 20: PANOVA-3: Patient characteristics
PRESENTED BY: PANOVA-3: Patients characteristics 20 Dr Vincent Picozzi CA19-9, carbohydrate antigen 19-9; ECOG PS, Eastern Cooperation Oncology Group performance status; GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor Treating Fields. TTFields + GnP (n=285) GnP (n=286) Overall (n=571) Median age (r
Slide 21: PANOVA-3: Treatment characteristics
PRESENTED BY: PANOVA-3: Treatment characteristics 21 Dr Vincent Picozzi GnP, gemcitabine/nab-paclitaxel; NA, not applicable; TTFields, Tumor Treating Fields. • Duration of exposure to gemcitabine and nab- paclitaxel was similar in the study arms • The distribution of salvage therapies was balanced b
Slide 22: Primary endpoint: overall survival
PRESENTED BY: Primary endpoint: overall survival Dr Vincent Picozzi ITT TTFields + GnP GnP P-value Median OS (95% CI) Events 16.2 (15.0, 18.0) 201 14.2 (12.8, 15.4) 230 0.039 HR = 0.82 (95% CI: 0.68, 0.99) 1-year survival rate, Median (95% CI) 68.1 (62.0, 73.5) 60.2 (54.2, 65.7) 0.029 22 ITT Populat
Slide 23: Secondary endpoints: PFS and local PFS
PRESENTED BY: Secondary endpoints: PFS and local PFS 23 Dr Vincent Picozzi PFS – ITT population Local PFS* – ITT population *Progressive disease per revised RECIST version 1.1 in the absence of distant metastasis, including non-regional lymph node metastasis, and abdominal metastases. CI, confidence
Slide 24: Post-hoc analysis: Distant PFS
PRESENTED BY: Post-hoc analysis: Distant PFS* 24 Dr Vincent Picozzi *Defined as progressive disease per revised RECIST version 1.1 in the absence of local progression. CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; PFS, progression-free s
Slide 25: Secondary endpoint: pain-free survival
PRESENTED BY: Secondary endpoint: pain-free survival* 25 Dr Vincent Picozzi CI, confidence interval; GnP, gemcitabine/nab-paclitaxel; HR, hazard ratio; ITT, intent-to-treat population; TTFields, Tumor Treating Fields; VAS, visual analogue scale. *Pain-free survival was defined as the time to a ≥ 20-
Slide 26: Quality of life: time to deterioration
PRESENTED BY: 26 Dr Vincent Picozzi *Defined as the first time-point a patient experienced a deterioration of ≥10 points in the respective QoL scale or death. GnP, gemcitabine/nab-paclitaxel; QoL, quality of life; TTFields; Tumor Treating Fields. ITT TTFields + GnP GnP P-value Median time to deterio
Slide 27: Safety summary
PRESENTED BY: Safety summary 27 Dr Vincent Picozzi AE, adverse event; GnP, gemcitabine/nab-paclitaxel; TTFields, Tumor Treating Fields. 1. Von Hoff DD, et al. NEJM 2013;369(18):1691-703. • Rates of AEs were similar between arms • Toxicity profile as expected for treatment with gemcitabine/nab-paclit
Slide 28: Device-related adverse events
PRESENTED BY: 28 Dr Vincent Picozzi Device-related AEs, n (%) TTFields + GnP (N=274) All grades Grade ≥3 Any AE 222 (81.0) 26 (9.5) Any serious AE 1 (0.4) 0 Any AE leading to TTFields discontinuation 23 (8.4) 7 (2.6) Any AE leading to death 0 0 AEs occurring in ≥2% of patients Dermatitis 76 (27.7) 8
Slide 29: Key Takeaway Points/Conclusions
PRESENTED BY: Key Takeaway Points/Conclusions 29 Survival benefit for patients is supported by significantly improved QoL and pain-free survival* compared with GnP alone Dr Vincent Picozzi The only frequently reported TTFields toxicity was localized skin reactions *as the time to a ≥ 20-point increa
Slide 30: TTFields With Gemcitabine and Nab-Paclitaxel: PANOVA-3 Publication
PRESENTED BY: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study ascopubs.org QR code here Check out the accompanying podcast, “TTFields in Locally Advanced Pancreatic Adenocarcinoma,” wit
Slide 31: Acknowledgements
PRESENTED BY: 31 Special thank you to all participating patients, their families, and clinical research teams for your commitment and contributions. Dr Vincent Picozzi Acknowledgements Medical writing support for this presentation was provided by Chelsea Higgins, Janin Knop and Christine Mormont of
Slide 32: [ ]
[Confidential] © 2025 Novocure GmbH © 2025 Novocure GmbH 32
Slide 33: Path to regulatory approval
© 2025 Novocure GmbH 33 path to regulatory approval Topline analysis Data presentation at ASCO Data publication in JCO FDA submission 2025 2026 TUV and PMDA submissions Commercial launch Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4Q4 REGULATORY REVIEW PERIODSUBMISSION ✓ ✓ ✓ REGULATORY REVIEW PERIODSUBMISSION
Slide 34: PANOVA-4 builds on promising clinical data
© 2025 Novocure GmbH 34 PANOVA-4 builds on promising clinical data for TTFields therapy with PD-(L)1 inhibitors PANOVA-4 phase 2 study delves deeper into TTFields therapy’s capabilities in pancreatic cancer • Studying TTFields therapy with atezolizumab + nab-paclitaxel / gemcitabine in metastatic pa
Slide 35: 2025 key objectives, unlocking TTFields potential
© 2025 Novocure GmbH 35 2025 key objectives, unlocking TTFields potential DRIVING COMMERCIAL ADOPTION ADVANCING CLINICAL PIPELINE DELIVERING PRODUCT INNOVATION NSCLC: drive global active patient growth and pursue reimbursement NSCLC: CE Mark achieved, launch underway in Germany • NSCLC: PMDA appro
Slide 36: Q&A
[Confidential] © 2025 Novocure GmbH © 2025 Novocure GmbH 36 Q&A Investor Event May 31, 2025 – Chicago
Slide 37: Appendix
PRESENTED BY: 37 Appendix Dr Vincent Picozzi
Slide 38: Array Layouts
PRESENTED BY: Array Layouts 38 Dr Vincent Picozzi A) Epigastric-centered with the superior discs row at the level of the xiphoid B) Left hypochondriac-shifted to the left with the superior discs row at the level of the xiphoid C) Right hypochondriac-shifted to the right with the superior discs row a
Slide 39: Array Layouts – continued
PRESENTED BY: Array Layouts – continued 39 Dr Vincent Picozzi E) Left lumbar-shifted to the left with the superior discs row at the inferior the 10th costal cartilage F) Right lumbar-shifted to the right with the superior discs row at the inferior border of the 10th costal cartilage. G) Large epigas
Slide 40: Secondary Endpoints in the mITT population
PRESENTED BY: Secondary Endpoints in the mITT population 40 Dr Vincent Picozzi mITT TTFields + GnP GnP P-value Median PFS (95% CI) Events 11.2 (9.4, 13.1) 136 10.7 (9.1, 11.5) 121 0.183 HR = 0.84 (95% CI: 0.66, 1.08) 1-year PFS rate, median (95% CI) 48.5 (40.5, 56.0) 38.7 (30.5, 46.8) 0.044 PFS Loca
Slide 41: Overall response rate (ITT population)
PRESENTED BY: Overall response rate (ITT population) 41 Dr Vincent Picozzi TTFields + GnP (n=244) GnP (n=243) Best overall response, n (%) CR 3 (1.2) 0 PR 85 (34.8) 73 (30.0) SD 142 (58.2) 150 (61.7) PD ORR, % (95% CI) 14 (5.7) 36.1 (30.0, 42.4) 20 (8.2) 30.0 (24.3, 36.2) Mean difference in ORR, % (
Slide 42: Salvage Therapies
PRESENTED BY: Salvage Therapies 42 Dr Vincent Picozzi Summary of Salvage Systemic Therapies TTFields + GnP (N=285) GnP (N=286) Number of Subjects Having Salvage Systemic Therapies 146 (51.2) 134 (46.9) Fluorouracil 92 (32.3) 78 (27.3) Irinotecan hydrocholide 85 (29.8) 69 (24.1) Folinic acid 75
Slide 43: Limitations
PRESENTED BY: Limitations 43 • Investigator's assesment of CT scans for response determination • While protocol included a clear definition of resectability at baseline, there was no such guidance for follow up visits • Gender imbalance between both arms • High discontinuation rate within the first